Estradiol agonists inhibit human LoVo colorectal-cancer cell proliferation and migration through p53

Figure 6 17β-estradiol and/or ER selective agonists inhibit human LoVo colorectal cancer cell motility through p53 signaling. LoVo cells cultured in DMEM were pretreated with vehicle, ICI 182780 (ER antagonist 1 μmol/L), p53 inhibitor (10 μmol/L), MPP (ERα antagonist 1 μmol/L), or PHTPP (ERβ antagonist 1 μmol/L) for 1 h, followed by treatment with E2 (10^-8 mol/L), PPT (10^-8 mol/L) or DPN (10^-8 mol/L) administration for 48h.The migration ability of LoVo cells was analyzed by a scratch motility assay (A) and a migration assay (B). The results were observed and analyzed with a fluorescence microscope. All experiments were repeated twice with identical results. ^aP < 0.05 vs control; ^bP < 0.01 vs control; ^dP < 0.01 vs E2.